CLINICAL ROLE -
Janssen Pharmaceuticals' Xarelto
The FDA approved Xarelto (rivaroxaban) for the prevention of venous thromboembolism following hip or knee replacements and for the prevention of stroke in patients with nonvalvular atrial fibrillation.
Read More
Real-World Outcomes Show Efficacy, Safety of Ciltacabtagene Autoleucel in Relapsed, Refractory Multiple Myeloma
Pharmacists as Patient Advocates: Ensuring Optimal Therapeutic Outcomes
Exploring the Benefits, Risks, and Clinical Implications of Herbal Supplements
Monitoring Kidney Function May Help Diagnose CKD in Patients Hospitalized for COVID-19